Analyst Price Targets — APLS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 27, 2026 9:23 pm | — | Barclays | $24.00 | $21.81 | TheFly | Apellis initiated with an Equal Weight at Barclays |
| January 20, 2026 11:06 am | — | Wells Fargo | $26.00 | $19.94 | TheFly | Apellis price target lowered to $26 from $29 at Wells Fargo |
| January 13, 2026 12:54 pm | — | Cantor Fitzgerald | $35.00 | $23.20 | TheFly | Apellis price target lowered to $35 from $39 at Cantor Fitzgerald |
| January 12, 2026 6:45 pm | — | Goldman Sachs | $19.00 | $23.20 | StreetInsider | Goldman Sachs on Apellis Pharmaceuticals (APLS): 'we see limited near-term growth levers' |
| December 19, 2025 12:47 pm | — | Stifel Nicolaus | $48.00 | $24.48 | TheFly | Apellis price target lowered to $48 from $55 at Stifel |
| November 3, 2025 11:36 am | Graig Suvannavejh | Mizuho Securities | $19.00 | $21.47 | StreetInsider | Apellis Pharmaceuticals (APLS) PT Lowered to $19 at Mizuho |
| October 31, 2025 11:25 am | — | Robert W. Baird | $52.00 | $20.73 | TheFly | Apellis price target raised to $52 from $50 at Baird |
| October 31, 2025 10:05 am | — | H.C. Wainwright | $45.00 | $20.73 | TheFly | Apellis price target lowered to $45 from $57 at H.C. Wainwright |
| October 29, 2025 12:46 pm | — | Mizuho Securities | $24.00 | $29.70 | TheFly | Apellis price target raised to $24 from $22 at Mizuho |
| October 15, 2025 9:20 am | — | Wells Fargo | $32.00 | $23.15 | TheFly | Apellis upgraded to Overweight from Equal Weight at Wells Fargo |
Latest News for APLS
WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that Mikael Dolsten, M.D.
APLS posts wider-than-expected Q4 loss as Syfovre sales slip 8%, but revenues top estimates and Empaveli surges 50% on a strong new indication launch.
Apellis Pharmaceuticals, Inc. (APLS) came out with quarterly earnings of $0.47 per share, beating the Zacks Consensus Estimate of a loss of $0.4 per share. This compares to a loss of $0.29 per share a year ago.
While the top- and bottom-line numbers for Apellis Pharmaceuticals (APLS) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Apellis Pharmaceuticals, Inc. (APLS) Q4 2025 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for APLS.
U.S. House Trading
No House trades found for APLS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.